# A Study to Evaluate ALKS 5461 in Subjects With Major Depressive Disorder (MDD)

> **NCT01500200** · PHASE2 · COMPLETED · sponsor: **Alkermes, Inc.** · enrollment: 142 (actual)

## Conditions studied

- Major Depressive Disorder

## Interventions

- **DRUG:** ALKS 5461
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01500200
- **Lead sponsor:** Alkermes, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-12
- **Primary completion:** 2013-03
- **Final completion:** 2013-03
- **Target enrollment:** 142 (ACTUAL)
- **Last updated:** 2019-05-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01500200

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01500200, "A Study to Evaluate ALKS 5461 in Subjects With Major Depressive Disorder (MDD)". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT01500200. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*